Search results for " Interleukin-5"

showing 5 items of 5 documents

Treating severe asthma:Targeting the IL‐5 pathway

2021

Abstract Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)‐4, IL‐5 and IL‐13). Monoclonal antibodies that target the eosinophilic inflammatory pathways (IL‐5R and IL‐5), namely mepolizumab, reslizumab, and benralizumab, are effective and safe for severe eosinophilic asthma. Eosinophils threshold represents the most indicative biomarker for response to treatment with all three monoclonal antibodies. Improvement in asthma symptoms scores, lung function, the number of exacerbations, history of late‐o…

0301 basic medicineImmunologyReview ArticleDisease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineReslizumabEosinophilicHumansImmunology and AllergyMedicineInvited ReviewsAnti-Asthmatic AgentsInterleukin 5Asthmabusiness.industryAnti-Asthmatic Agents Asthma Eosinophils Interleukin-5medicine.diseaseBenralizumabAsthmaEosinophils030104 developmental biology030228 respiratory systemchemistryImmunologyBiomarker (medicine)Interleukin-5businessMepolizumabmedicine.drug
researchProduct

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma

2018

Asthma is a very frequent chronic airway disease that includes many different clinical phenotypes and inflammatory patterns. In particular, eosinophilic bronchial inflammation is often associated with allergic as well as nonallergic asthma. The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2). Hence, IL-5 and its receptor are suitable targets for selective biologic drugs which can play a key role in add-on treatment of severe eosinophilic asthma refractory to corticosteroids. Within such a context, the anti-IL-5 mon…

Genetics and Molecular Biology (all)0301 basic medicineImmunology and Microbiology (all)lcsh:MedicineReview ArticleAntibodies Monoclonal HumanizedBiochemistryAntibodiesGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compoundTh2 Cells0302 clinical medicineReslizumabMonoclonalEosinophilicmedicineAnimalsHumansEosinophiliaHumanizedInterleukin 5AsthmaGeneral Immunology and Microbiologybusiness.industrylcsh:RInnate lymphoid cellGeneral Medicinemedicine.diseaseBenralizumabAsthmarespiratory tract diseasesBiological Therapy030104 developmental biology030228 respiratory systemchemistryImmunologyInterleukin-5medicine.symptombusinessMepolizumabAnimals; Antibodies Monoclonal Humanized; Asthma; Biological Therapy; Humans; Interleukin-5; Th2 Cells; Biochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)medicine.drug
researchProduct

Noninvasive methods for the detection of upper and lower airway inflammation in atopic children

2006

Background Exhaled nitric oxide (FE NO ) and exhaled breath condensate (EBC) are noninvasive methods to assess inflammation. Objective To investigate the role of the FE NO and of the EBC pH and IL-5 levels in atopic children. Methods We evaluated oral and nasal FE NO and the pH and IL-5 of oral and nasal EBC in children with atopic dermatitis (AD; n=18), allergic rhinitis (AR; n=18), intermittent asthma (n = 21), moderate persistent asthma (n = 18), and healthy controls (HCs; n=16). Results Oral FE NO was significantly increased in asthma, whereas the nasal values were increased in AR and asthma in comparison with HCs. The pH of oral EBC was lower in AD and asthma than in AR and HCs, wherea…

MaleAllergyRhinitis Allergic PerennialAdolescentImmunologyBronchitiNitric OxideDermatitis AtopicAtopymedicineImmunology and AllergyHumansExhaled breath condensateExpirationBronchitisChildInflammation MediatorAsthmabusiness.industryMouth MucosaRhinitis Allergic SeasonalAtopic dermatitisDermatitis Atopic; Mouth Mucosa; Exhalation; Humans; Hydrogen-Ion Concentration; Asthma; Child; Nitric Oxide; Rhinitis Allergic Perennial; Rhinitis Allergic Seasonal; Interleukin-5; Nasal Mucosa; Inflammation Mediators; Bronchitis; Adolescent; Female; MaleHydrogen-Ion Concentrationmedicine.diseaseAsthmarespiratory tract diseasesNasal Mucosamedicine.anatomical_structureExhalationImmunologyExhaled nitric oxideFemaleInflammation MediatorsInterleukin-5businessRespiratory tractHuman
researchProduct

Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis …

2001

ABSTRACT The aim of this study was to compare pertussis-specific humoral and cellular immunity in children 5 years after a primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine (DTaP-HBV; InfanrixHepB; SmithKline Beecham) with immunity after natural infection. The subjects were 38 children aged 5 to 6 years who received DTaP-HBV at 3, 5, and 11 months of life and 21 subjects of similar ages and sex who acquired pertussis in the first year of life. Immunoglobulin G (IgG) antibody titers against Bordetella pertussis antigens, peripheral blood mononuclear cell-specific proliferation, and the secretion of cytokines were evaluated. Aft…

MaleBordetella pertussisCellular immunityTime FactorsHepatitis B vaccineWhooping CoughImmunologyMicrobiologyBordetella pertussisAntibodiesInterferon-gammaImmunitymedicineHumansHepatitis B VaccinesSingle-Blind MethodVaccines CombinedLymphocytesChildPreschoolDiphtheria-Tetanus-Pertussis VaccineWhooping coughHaemophilus VaccinesVaccinesbiologyVaccines; Combined; Interferon-gamma; Humans; Whooping Cough; Hepatitis B Vaccines; Child; Lymphocytes; Diphtheria-Tetanus-Pertussis Vaccine; Vaccination; Preschool; Bordetella pertussis; Single-Blind Method; Interleukin-2; Antibodies; Bacterial; Haemophilus Vaccines; Interleukin-4; Interleukin-5; Time Factors; Male; Female; Cell DivisionCombinedTetanusbusiness.industryDiphtheriaCELL-MEDIATED-IMMUNITYVaccinationBacterialbiology.organism_classificationmedicine.diseaseAntibodies BacterialVirologyVaccinationInfectious DiseasesChild PreschoolMicrobial Immunity and VaccinesImmunologyInterleukin-2FemaleParasitologyInterleukin-4Interleukin-5businessCell Division
researchProduct

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.

2019

Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma. However, while OCS are effective at treating acute exacerbations, there is only empirical evidence regarding the efficacy of OCS at reducing the rate of exacerbations. Evidence, although scarce, is suggestive of high exacerbation rates in severe asthma patients even when receiving maintenance treatment with OCS. In addition, use of OCS is associated with undesirable effects. Despite all this, physicians have continued to use OCS for managing severe asthma and acute exacerbation due to the lack of availability of effective…

Pulmonary and Respiratory MedicineMaleAllergymedicine.medical_specialtyExacerbationInjections SubcutaneousAdministration OralOmalizumabOmalizumabAntibodies Monoclonal HumanizedSeverity of Illness Indexchemistry.chemical_compoundReslizumabAdrenal Cortex HormonesInternal medicinemedicineHumansAnti-Asthmatic AgentsAsthmaBiological Productsbusiness.industryInterleukin-4 Receptor alpha SubunitImmunoglobulin Emedicine.diseaseBenralizumabReceptors Interleukin-5DupilumabAsthmachemistryAdministration IntravenousFemaleInterleukin-5businessMepolizumabmedicine.drug
researchProduct